Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
Tiziana Life Sciences (NASDAQ:TLSA), a biotechnology company focused on immunomodulation therapies, has been invited to the J.P. Morgan Asset Management Life Science Innovation Forum (LSIF) 2025 in Riyadh, Saudi Arabia. The event will take place on October 1-2, 2025 at the King Saud bin Abdulaziz University for Health Sciences Conference Center.
The forum aims to accelerate life science research commercialization and strengthen the biotechnology value chain in Saudi Arabia. The company will have the opportunity to present its clinical pipeline, including its lead candidate intranasal foralumab, a fully human anti-CD3 monoclonal antibody, to potential investors and strategic partners.
Tiziana Life Sciences (NASDAQ:TLSA), una società biotecnologica focalizzata sulle terapie immunomodulanti, è stata invitata al J.P. Morgan Asset Management Life Science Innovation Forum (LSIF) 2025 a Riad, Arabia Saudita. L’evento si svolgerà il 1-2 ottobre 2025 presso il King Saud bin Abdulaziz University for Health Sciences Conference Center.
Il forum ha l’obiettivo di accelerare la commercializzazione della ricerca nelle scienze della vita e di rafforzare la catena del valore biotecnologica in Arabia Saudita. L’azienda avrà l’opportunità di presentare il suo portafoglio clinico, incluso il suo candidato principale intranasal foralumab, un anticorpo monoclonale anti-CD3 completamente umano, a potenziali investitori e partner strategici.
Tiziana Life Sciences (NASDAQ:TLSA), una empresa de biotecnología centrada en terapias de inmunomodulación, ha sido invitada al J.P. Morgan Asset Management Life Science Innovation Forum (LSIF) 2025 en Riad, Arabia Saudita. El evento se llevará a cabo los días 1-2 de octubre de 2025 en el King Saud bin Abdulaziz University for Health Sciences Conference Center.
El foro tiene como objetivo acelerar la comercialización de la investigación en ciencias de la vida y fortalecer la cadena de valor de la biotecnología en Arabia Saudita. La empresa tendrá la oportunidad de presentar su cartera clínica, incluido su candidato principal intranasal foralumab, un anticuerpo monoclonal anti-CD3 completamente humano, a posibles inversores y socios estratégicos.
Tiziana Life Sciences (NASDAQ:TLSA), 면역 조절 치료에 집중하는 생명공학 회사가 LSIF 2025로 초청받았습니다. 이 행사는 사우디아라비아 리야드에서 열리며, 2025년 10월 1-2일에 King Saud bin Abdulaziz University for Health Sciences Conference Center에서 개최됩니다.
포럼의 목적은 생명과학 연구의 상용화를 가속하고 사우디아라비아의 생명공학 가치 사슬을 강화하는 것입니다. 이 회사는 잠재 투자자 및 전략적 파트너에게 intranasal foralumab를 포함한 임상 파이프라인을 발표할 기회를 갖게 될 것입니다. intranasal foralumab은 완전 인간형 anti-CD3 단일클론 항체입니다.
Tiziana Life Sciences (NASDAQ:TLSA), une société biotechnologique axée sur les thérapies d’immunomodulation, a été invitée au J.P. Morgan Asset Management Life Science Innovation Forum (LSIF) 2025 à Riyad, en Arabie Saoudite. L’événement se déroulera les 1er et 2 octobre 2025 au King Saud bin Abdulaziz University for Health Sciences Conference Center.
Le forum vise à accélérer la commercialisation de la recherche en sciences de la vie et à renforcer la chaîne de valeur biotechnologique en Arabie Saoudite. L’entreprise aura l’occasion de présenter son portefeuille clinique, y compris son candidat principal intranasal foralumab, un anticorps monoclonal anti-CD3 entièrement humain, à des investisseurs potentiels et partenaires stratégiques.
Tiziana Life Sciences (NASDAQ:TLSA), ein biotechnologisches Unternehmen mit Schwerpunkt auf Immunmodulationstherapien, ist zum J.P. Morgan Asset Management Life Science Innovation Forum (LSIF) 2025 in Riad, Saudi-Arabien, eingeladen worden. Die Veranstaltung findet am 1.–2. Oktober 2025 im Konferenzzentrum der King Saud bin Abdulaziz University for Health Sciences statt.
Das Forum zielt darauf ab, die Kommerzialisierung von Lebenswissenschaftsforschung zu beschleunigen und die Biotechnologie-Wertschöpfungskette in Saudi-Arabien zu stärken. Das Unternehmen wird die Gelegenheit haben, seinen klinischen Pipeline-Fahrplan vorzustellen, einschließlich seines führenden Kandidaten intranasal foralumab, eines vollständig menschlichen anti-CD3-Monoklonalantikörpers, potenziellen Investoren und strategischen Partnern zu präsentieren.
Tiziana Life Sciences (NASDAQ:TLSA)، شركة تكنولوجيا حيوية تركز على علاجات تعديل المناعة، مدعوة إلى منتدى J.P. Morgan Asset Management للابتكار في علوم الحياة (LSIF) 2025 في الرياض، المملكة العربية السعودية. سيعقد الحدث في 1-2 أكتوبر 2025 في مركز مؤتمرات جامعة الملك سعود بن عبدالعزيز للعلوم الصحية.
يهدف المنتدى إلى تسريع تسويق أبحاث علوم الحياة وتقوية سلسلة قيمة التكنولوجيا الحيوية في المملكة العربية السعودية. ستكون الشركة لديها الفرصة لعرض خطها العلاجي السريري، بما في ذلك مرشحها الرائد intranasal foralumab، وهو جسم مضاد أحادي النسيلة ضد CD3 بشكل كامل الإنسان، أمام المستثمرين المحتملين وشركاء استراتيجيين.
Tiziana Life Sciences (NASDAQ:TLSA)，一家专注于免疫调节治疗的生物技术公司，已被邀请参加在沙特阿拉伯利雅得举行的 J.P. Morgan Asset Management Life Science Innovation Forum (LSIF) 2025。该活动将于 2025年10月1-2日 在 King Saud bin Abdulaziz University for Health Sciences Conference Center 举行。
论坛旨在加速生命科学研究的商业化，并巩固沙特阿拉伯的生物技术价值链。公司将有机会向潜在投资者和战略伙伴展示其临床管线，包括其领先候选药物 intranasal foralumab，这是一种完全人源的 anti-CD3 单克分子抗体。
- None.
- None.
BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it has been invited to attend the J.P. Morgan Asset Management, Life Science Innovation Forum (LSIF) 2025 in Collaboration with KAIMRC, taking place October 1–2, 2025, at the King Saud bin Abdulaziz University for Health Sciences Conference Center in Riyadh, Saudi Arabia.
The 2025 Life Science Innovation Forum (LSIF) is a two-day international event hosted in Riyadh, Saudi Arabia. This prestigious forum serves as a platform to accelerate the conversion of cutting-edge life science research into market-ready solutions. It aims to strengthen the biotechnology value chain by connecting groundbreaking scientific innovators with strategic investors and industry leaders. Aligned with the National Biotechnology Strategy, the forum is designed to foster a thriving, innovation-driven ecosystem that positions Saudi Arabia at the forefront of the global life sciences sector. It has been organized to establish a strong foundation for both regional and global progress in life sciences research, innovation, industry, regulation, and investment. The event will feature presentations from leading biotech companies, panel discussions, and networking sessions aimed at facilitating investment, collaboration, and strategic partnerships.
“Tiziana is honored to be among the innovative companies invited to LSIF 2025,” said Ivor Elrifi, CEO of Tiziana Life Sciences. “This event represents a unique opportunity to engage with global investors, showcase our clinical pipeline, and explore strategic collaborations that will advance our mission to deliver next-generation immunotherapy solutions to patients worldwide.”
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120
FAQ
When and where will Tiziana Life Sciences (TLSA) present at the LSIF 2025 conference?
What is Tiziana Life Sciences' (TLSA) lead drug candidate?
What is the purpose of the Life Science Innovation Forum 2025 in Saudi Arabia?
Who is the CEO of Tiziana Life Sciences (TLSA)?
